Disposable vs. Reusable Injection Pens: A Comprehensive Technical Selection Guide for Pharmaceutical Manufacturers

Introduction

The global injection pen market has experienced remarkable growth, valued at USD 44.68 billion in 2025 and projected to reach USD 113.58 billion by 2034, exhibiting a compound annual growth rate of 10.98%. Simultaneously, the self-injection devices market is expanding rapidly, with projections showing growth from USD 5.52 billion in 2026 to USD 15.11 billion by 2034. This explosive growth is driven by rising chronic disease prevalence, increasing adoption of biologic therapies, and a growing emphasis on patient-centric, self-administration drug delivery solutions.

For pharmaceutical manufacturers and packaging professionals, the choice between disposable and reusable injection pen platforms represents one of the most consequential decisions in product development. This technical guide provides a comprehensive framework for evaluating these options, integrating the latest industry data, regulatory requirements, and material science advancements.

At Vialab Pharmaceutical Packaging Co., Ltd., we specialize in the design and manufacture of high-quality drug delivery and packaging components—from injection pens to sterile vials—engineered to meet strict pharmaceutical standards. With advanced production lines and cleanroom facilities, we ensure consistent quality, integrity, and compliance for global healthcare partners.

1. Platform Overview: Understanding the Fundamental Differences

Disposable Injection Pens

Disposable injection pens are prefilled, single-use devices designed for administration over a defined period—typically one to four weeks—before being discarded. These devices come with the drug pre-loaded, eliminating the need for cartridge replacement. They are commonly used for high-volume therapies, commercial launches, and biologics requiring precise dosing. Disposable autoinjectors are often preferred by end users due to their simplicity and ease of use.

Reusable Injection Pens

Reusable injection pens are multi-use devices that employ standardized medication cartridges. Users replace the cartridge when empty while the pen body remains in service for extended periods. These pens are often selected for long-term therapies and markets prioritizing sustainability and lifecycle cost reduction. Studies show that 60% of users prefer reusable devices over disposable alternatives, appreciating their environmental benefits and added features despite involving more operational steps.

2. Design and Engineering Considerations

Reusable Pens: Precision Engineering for Durability

Reusable pen injectors demand robust, precision engineering to withstand repeated use while maintaining dosing accuracy. Key design requirements include:

• Durable Materials: Medical-grade stainless steel, reinforced polymers, and precision-engineered components capable of withstanding wear
• Advanced Mechanisms: Electro-mechanical dose-setting systems with complex mechanical springs
• Cartridge Compatibility: Universal or brand-specific refill systems ensuring proper engagement and sealing
• Safety Features: Automatic needle retraction, dose memory locks, and user error prevention mechanisms

Reusable pens require higher initial manufacturing costs due to complex parts and assembly processes. Factories invest more in quality control, precision machining, and testing to ensure durability and safety.

Disposable Pens: Efficiency and Accessibility

Disposable pen injectors prioritize efficiency and accessibility through:

• Lightweight Construction: Optimized single-use plastics with minimal moving parts
• Simplified Assembly: High-speed injection molding and automated assembly lines
• Pre-Filled Integration: Sterile drug reservoirs requiring aseptic filling lines

Disposable pens benefit from simpler designs and mass production techniques like injection molding, enabling factories to produce large volumes quickly and at lower per-unit cost.

3. Material Selection: The Glass-to-Polymer Transition

Material selection profoundly impacts device performance, drug compatibility, and patient safety. The primary drug container (cartridge) represents a critical component in both disposable and reusable systems.

Glass Primary Drug Containers

Borosilicate glass has been the standard for over 100 years in injectable therapies. In 2024, the glass materials segment held a 52.4% market share. However, the industry is increasingly moving away from glass due to:

• Susceptibility to breakage during manufacturing, shipping, and use
• Higher weight compared to polymer alternatives
• Lower compatibility with sensitive compounds, particularly in modern biologic therapies

At Vialab, we continue to offer glass vials and tubes in parenteral grade with precise dimensions, recognizing that glass remains essential for many legacy therapies and traditional applications. Our commitment to quality ensures that every glass component meets the highest pharmaceutical standards.

Polymer Primary Drug Containers

Polymer technologies, particularly cyclic olefin polymers (COP) and cyclic olefin copolymers (COC), are gaining significant traction. The global cyclic olefin polymer market is valued at approximately USD 1.34 billion in 2025 and is projected to grow at a CAGR of 6.8%.

Key advantages of polymer cartridges include:

• Greater durability: Polymer syringes are much less likely to fracture in autoinjector applications
• Design flexibility: Unlike glass with limitations in shaping and tolerance control, COC can be molded into complex, integrated forms with tight dimensional accuracy
• Reduced contamination risk: Polymeric primary drug containers resolve many known issues with glass while unlocking opportunities for biologic delivery
• Ultra-high purity: Engineered polymers like COC offer extremely low off-gas and leachable content

SCHOTT Pharma has recently launched the first ready-to-use polymer cartridge made from COC, delivering functional performance comparable to glass with added break resistance. Polymer cartridges accounted for 30% of the pharmaceutical cartridges market in 2024 and are projected to grow at the fastest CAGR due to increasing demand for break resistance, lightweight designs, and biologics compatibility.

Vialab’s Material Capabilities

At Vialab, we provide comprehensive packaging solutions across both material platforms:

• Glass Vials & Tubes: Parenteral grade with precise dimensions
• Sterile Vials: Ready-to-use, wash and sterilized options
• Aluminum & Aluminum-Plastic Caps: Tamper-evident, available in various sizes

This dual capability allows us to serve as a single-source partner for pharmaceutical manufacturers transitioning between or operating across both material platforms.

4. Regulatory Compliance and Quality Standards

Both disposable and reusable injection pens must meet stringent regulatory requirements from agencies including the FDA and EMA.

ISO 11608 Series Standards

The ISO 11608 series serves as the core international standard for needle-based injection systems. These standards cover:

• Accurate dose control: Ensuring each injection delivers within the permitted margin of error
• Mechanical reliability: Verifying the device withstands repeated use without functional failure
• User safety: Requirements for mis-operation prevention and needle protection
• Environmental and transport adaptation: Ensuring drug stability during storage and distribution

The 2025 amendments to ISO 11608 further refine requirements for containers and integrated fluid paths. Specifically, ISO 11608-3:2022/DAM 1:2025 addresses containers and integrated fluid paths, reflecting the industry’s evolution toward more sophisticated drug delivery systems.

FDA Requirements

The FDA treats pen injectors and drugs as combination products, requiring complete validation data on safety and effectiveness. Examples of such combinations include injector pens for GLP-1 agonists such as Wegovy®, prefilled syringes, and other drug-device combinations.

In June 2025, the FDA released updated guidance on Unique Device Identification (UDI) for combination products, with specific requirements varying by product type. Device-led products must use UDI, while drug/biological-led products use NDC.

Additional Testing Requirements

Reusable pens require additional validation:

• Extended cycle durability testing (thousands of cycles)
• Cartridge interchangeability proofs
• Software validation for digital pens

Both systems require:

• Human factors validation per IEC 62366
• Biocompatibility certification under ISO 10993-1
• Sterilization validation (EO or radiation for disposables; cleaning validation for reusables)

Meeting ISO/FDA/EMA requirements minimizes risks of product recalls, clinical complications, and regulatory penalties. At Vialab, our strict quality control and ISO/GMP compliance ensure that every component meets these rigorous standards.

5. Manufacturing Complexity and Cost Analysis

Cost Structure Comparison

Factor	Reusable Pens	Disposable Pens
Unit Cost	Higher initial cost	Lower per-unit cost
Tooling Investment	Precision machining required	High-volume mold focus
Labor Intensity	Skilled technical assembly	Automated production lines
Long-term Economics	Lower cost per dose over time	Higher cumulative cost

Economic Considerations

While the initial acquisition cost of a reusable pen is higher than a disposable one, the long-term economic benefits are undeniable for chronic disease management. Insulin cartridges are often 15% to 20% cheaper than pre-filled disposable pens. Reusable pens achieve break-even points after a certain number of uses, making them more economical for long-term therapies.

Disposable pens, on the other hand, achieve economies of scale at high production volumes, making them ideal for commercial launches and therapies with shorter treatment durations.

Supply Chain Dynamics

Disposable Pens simplify logistics through:

• Integrated drug-device combinations
• Streamlined distribution as single SKUs
• Just-in-time manufacturing reducing inventory

Reusable Pens require:

• Separate supply chains for pen bodies and cartridges
• Cartridge ecosystem management
• Extended product lifecycle planning

6. Customization and Branding Opportunities

Both platforms offer unique opportunities for pharmaceutical branding and patient engagement.

Disposable Pens

• Full-device branding and color customization
• Integrated patient education materials
• Single-use convenience enhancing patient adherence

Reusable Pens

• Premium device aesthetics supporting brand positioning
• Cartridge-level branding and differentiation
• Long-term patient engagement through device ecosystems

At Vialab, we provide customized packaging solutions including pen cases and accessories, enabling pharmaceutical partners to create distinctive brand experiences across both disposable and reusable platforms.

7. Decision Framework for Pharmaceutical Manufacturers

When to Choose Disposable Pens

• Commercial launches requiring rapid market entry
• Therapies with short treatment durations (weeks to months)
• High-volume products benefiting from economies of scale
• Markets prioritizing convenience and ease of use
• Biologics and sensitive compounds where cartridge handling risks must be minimized

When to Choose Reusable Pens

• Chronic conditions requiring long-term therapy (diabetes, autoimmune disorders)
• Sustainability-focused markets prioritizing waste reduction
• Premium brand positioning leveraging device aesthetics
• Established therapies with predictable patient populations
• Markets where cartridge cost savings (15-20%) outweigh device costs

8. Future Trends and Innovations

Digital Health Integration

Connected injection pens with Bluetooth connectivity and smartphone apps are emerging across both platforms. These devices capture and transmit dosing information, improving adherence monitoring and clinical outcomes.

Sustainability Initiatives

Environmental concerns are driving innovation in both platforms:

• Reusable pens: Reduced plastic waste and carbon emissions
• Disposable pens: Development of recyclable and bio-based materials

Advanced Materials

The transition from glass to polymer primary drug containers continues to accelerate. Polymer cartridges offer superior break resistance, design flexibility, and compatibility with sensitive biologics.

Conclusion

The choice between disposable and reusable injection pens is not merely a technical decision—it is a strategic one that impacts product development timelines, manufacturing costs, regulatory pathways, patient adherence, and environmental sustainability. Pharmaceutical manufacturers must carefully evaluate their specific therapy requirements, patient populations, market positioning, and long-term commercial objectives.

At Vialab Pharmaceutical Packaging Co., Ltd., we bring decades of expertise in pharmaceutical packaging and drug delivery components to support our partners through this critical decision-making process. From injection pens (disposable and reusable) to glass vials, sterile vials, and aluminum caps, our comprehensive product portfolio and commitment to quality ensure that your drug delivery system meets the highest standards of safety, reliability, and patient satisfaction.

Whether you are launching a new biologic, expanding an existing product line, or exploring sustainable packaging alternatives, our team of packaging experts is ready to provide the technical guidance and manufacturing excellence you need to succeed in this rapidly evolving market.

---

Contact Vialab Pharmaceutical Packaging Co., Ltd. today to discuss your injection pen packaging requirements and discover how our precision pharmaceutical packaging solutions can support your next product launch.